ABSTRACT
INTRODUCTION -OBJECTIVE AND BACKGROUND
In Ayurveda, different types of drug and treatment modalities are described for heavy bleeding during menses (Asrigdara), among them, uttar basti is described as best for gynecological problems. So, in present study, Darvyadi Kashaya (Decoction made up of eight herbs i.e. Daruharidra (Berberis aristata), Rasanjana (extract of Berberis aristata in milk-Berberis aristata was boiled with milk, till it became solid in consistency), Kiratatikta (Swertia chirata), Mustak bleeding, but keeping the concept of uttar basti to treat gynecological diseases in the best way [ Sushruta] , the oil processed with the same decoction was also selected alone, along with decoction for comparative study. For standardization of the effect of these drugs, biomarker serum VEGF-A was selected because of its extensive role (on vasodilatation, vascular fragility and permeability) in pathogenesis of heavy menstrual bleeding in DUB .
MATERIAL AND METHODS

Selection of Cases
Patients attending to the outpatient department of Prasuti Tantra S.S. Hospital, B.H.U., Varanasi were randomly selected. The cases selected were having complaints of excessive and/or prolonged blood loss, during menstruation or short inter-menstrual period.
Criteria for Inclusion
• Married women of reproductive age group, with complaints of excessive bleeding per vagina during menstruation, either in amount or in duration or both or short inter menstrual period for 3 consecutive menstrual cycles were selected.
• Patients, who are neither using oral contraceptive pills nor IUCD for contraception or hormonal treatment.
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• The patients of reproductive age were included in the study, irrespective of obstetric history related to parity.
• The patients who were ready for consent, necessary investigations and agreed to come for follow up regularly selected.
• Infections such as candidiasis, Trichomonaliasis or any other form of vulvovaginitis and pelvic congestion were initially treated with respective drugs, and when symptoms and signs totally disappeared, then they were included in the study.
Criteria for Exclusion: Criteria for Exclusion
Associated with any currently ongoing research study, Unmarried, Postmenopausal, Recent delivery or abortion, 
Grouping of Cases
In the present study, assessment of said compounds in Asrigdara was studied in 120 patients, dividing into three groups A, B, C respectively. 
Doses
• Kashaya -20 ml twice a day with 10 ml honey
• Duration: 3 months
• Route of administration: Oral
• Basti-3-5ml ( in increasing order) for three days in a month, after clearance of menses Duration: 3 months
Route of administration: Vaginal
Follow Up Study
Total four follow ups were done. The cases were followed at monthly interval for 3 months with treatment after clearance of menses, and one last follow up was done after month after clearance of menses without drug, so as to note any recurrence of symptoms. 
History
The detailed history of the present complaints, with duration and associated symptoms was taken on pre-designed specific proforma. Detailed interrogation regarding present symptoms, especially the amount of blood loss, duration and interval of menses and other associated symptoms were taken.
History of past illness(if any) including diabetes mellitus, hypertension, Tuberculosis, Jaundice, Bronchial Asthma, Surgical intervention, Blood transfusion, drug sensitivity were noted. Personal history regarding habits, previous menstrual history, and obstetric history, including psychological upset, mania and psychosis was recorded. Family history was also noted. Other important points like marital status, status of hygiene, personal history and socioeconomic status were also noted.
Clinical Examinations
General Examination
General condition of the patient, Pulse, Temperature, Blood pressure, Pallor, Icterus, Clubbing, Cyanosis, Edema, Lymphadenopathy etc. noted.
Systemic Examination
Examination of central nervous system, gastrointestinal tract, respiratory system, cardiovascular system, urogenital systems were done.
Local Examination
Local examination of reproductive system was done thoroughly. The condition of the vulva and vagina was noted.
P/S (per speculum) examination was done to know the condition of the cervix for congestion, hypertrophy, erosion, ectropion, entropion, nebothian follicles, any discharges (It's amount, color, odor and consistency). Per vaginal examination was done to know the size, shape, direction, mobility and consistency of the uterus with the condition of the adnexae and the observations were recorded.
Investigations Advised
After detailed history and complete examinations, all the cases were subjected to following investigations before the trial. • Urine Examination: For routine and microscopic examination. For culture and sensitivity test (if needed)
• Stool Examination : for ova and cyst • Endometrial Biopsy (if needed, in patients having age >35 yrs)
Criteria of Assessment
Scoring of the symptoms was done before and after the study, purely on the basis of patient's explanations.
Duration of Menstrual Bleeding
Duration of bleeding was categorized according to bleeding occurring in total number of days. This was noted as per the patient's explanations.
Inter-Menstrual Period
The number of days in between two consecutive menstrual cycles was counted.
Amount of Blood Loss
It was assessed on the basis of statements given by the patient. All the patients were advised to use a standard size pad "Stay Free secure" (Johnson & Johnson) having average pad weight 12.5 gm, asked to change the pad, when it is fully soaked and note the count of the pad used per day during menstruation. Hence, the number of pads used in every cycle recorded. 
Observations
The observations of the patients of all the three groups are discussed further on the basis of history (age, gravidity, parity, marital status, chief complaints with duration, personal history etc.), physical examination, local examination, investigations and different parameters like the duration of bleeding, inter menstrual period, amount of bleeding and associated symptoms.
Follow Up
Patient of both group were followed up at regular interval of one month (after bleeding is complete) for the evaluation of drug on present complaints and associated complaints. Three follow up study were done, while the patient was on drugs (then the drug was withdrawn) and fourth follow up was taken without drug to check the efficacy of treatment and to know the status of symptoms of the patients. Specific scoring of duration of bleeding, intermenstrual period, amount of bleeding, consistency of menstrual blood and change in associated symptoms were also recorded. human VEGF coated on wells in ELISA plate. Standards and sample were pipetted into the wells, and the VEGF present in a sample was bound to the wells by the immobilized antibody. HRP-conjugated streptovidin was pipetted to the wells.
Sample Collection for Estimation of
The wells were again washed, a TMB substrate solution was added to the wells and color developed in proportion to the amount of VEGF bound. The stop solution changed the color from blue to yellow, and the color was measured at 450nm
by the ELISA plate reader. 
Assay Procedure
• 100 µl of each standard and sample were added into appropriate wells. Wells were covered and incubated for 2.5
hours at room temperature.
• After 2.5 hours, the solution was discarded and the wells were washed 4 times with 1 x wash solution.
Washing was done by filling each well with wash buffer (300 µl) using a Multi Channel pipette. Complete removal of liquid at each step was done for good performance. After the last wash, the plate was inverted and blotted against clean paper towel.
• 100 µl of 1x prepared biotinylated antibody was added to each well and the plate was again incubated for 1 hour at room temperature.
• After 1 hour, solution was again discarded and 4 times washing was again done with 1x wash solution.
• 100µl of the prepared streptavidin solution was added to each well, again the plate was incubated for 45 minutes at room temperature with gentle shaking.
• After 45 minutes, again solution was discarded and 4 times washing of the ELISA plate was done by 1x wash solution.
• 100µl of TMB one step substrate reagent (item H) was added to each well, and the plate was incubated for 30 minutes at room temperature in dark with gentle shaking.
• After 30 minutes, 50µl of stop solution (Item I) was added to each well, and ELISA plate was read at 450nm to measure respective optical density of each well by the ELISA plate reader. 
RESULTS Its Evaluation by Assesing Biomarker
Graph 4: Showing Improvement in Serum VEGF-A after Treatment in all the Three Groups
So, it can be said that raised concentration of serum VEGF-A is a cumulative expression of various pathological events, those are going on at various level of endometrium, and body and reduction of its concentration shows that the drug has acted on those pathological factors.
Results show that serum VEGF-A level gets reduced in all the three groups which were statistically significant, but the improvement was more (p>.001 ) in trial group C, in which patients took oral drug with uttar basti.
DISCUSSIONS
Heavy, prolonged and frequent bleeding is often considered as dysfunctional uterine bleeding (DUB), which is devoid of any pregnancy causation or systemic disease, hormonal disturbance is considered to be one of the causes of There are several angiogenic growth factors in the human endometrium, which are responsible for the endometrial vascular integrity and permeability, and any disturbance in these causes bleeding, as in case of DUB.
The most celebrated actions of VEGF-A are in endothelial cells, inducing proliferation and migration.
A possible additional effect of VEGF-A on the vasculature is that of vasodilatation. VEGF-A stimulates nitric oxide release from endothelial cells. VEGF-A also induces the release of prostacyclin, another vasodilating agent, by activating cytosolic phospholipase A2, causing the release of arachidonic acid. Both of these effects could modulate the contractility of the spiral arterioles, and thus alter the volume of menstrual blood loss.
In addition to its actions on the endothelial cells, VEGF-A has important effects on serine proteinases which influence coagulation. This is important in the context of the endometrium, as coagulation (Gleeson, et al., 1993) here differs from that in other regions of the body, in that, rapid coagulation and fibrinolysis of the blood occurs as it passes down the spiral arterioles. This is presently thought to be an important part of the mechanism of excessive menstrual bleeding. Elevated levels of tissue plasminogen activator (tPA) are found in endometrium of women with heavy periods and drugs, which reduce the degradation of fibrin platelet clots to fibrin degradation products, reducing menstrual blood loss by about 50% (Cameron, et al., 1995) .
INCREASED ENDOMETRIAL VASCULAR FRAGILITY
It is regulated by-
• Hormonal regulation
• Inflammatory regulation
• Oxidative Stress
Hormonal Regulation
Due to hormonal imbalance (unopposed estrogen in case of DUB) at the level of uterine endometrium, there is increased dilatation of the arterial supply in the endometrium and lead to proliferation of endometrium, and would associate with abnormal thickening of the endometrium without proper architectural integrity.
Large, thin-walled, tortuous, superficial endometrial vessels often can be demonstrated on the surface of the endometrial hyperplasia; increase of blood loss is due to fragility of blood vessels. Vascular tone is reduced by an unopposed estrogen and has a direct effect by inhibiting vasopressin release, that causes vasodilatation and increase blood flow (Springer-Verlag; 1985).
When estrogen synthesis is uneven and unopposed, synthesis of prostaglandin (PG) in endometrium would be less, and in this condition synthesis of prostaglandin E is higher than PGF.
Inflammatory Regulation
Multiple mechanisms involve in the accuracy of the angiogenic balance between angiogenic factors and interaction with a compound of extracellular matrix (ECM ).
ECM is considered to be the storage place for angiogenic stimulator and inhibitors. These molecules are found to Among all the growth factors, vascular endothelial growth factor (VEGF), is considered to be a potent and best studied angiogenic peptide that is released from ECM by the proteolytic action of MMPs and plasmin.
The activity of MMPs on angiogenic growth factors, chemokines, growth factor receptors, apoptosis mediators, adhesion molecules is critical for the rapid cellular responses, and essential for angiogenesis and also involved in mediating tumor growth and progression.
VEGF is regulated by a variety of stimuli such as hypoxia, growth factors, exogenous growth factor stimulator, transformation, mutation, estrogen, TSH(thyroid-stimulating hormone), tumor promoters and NO (nitric oxide) (Agrez M, et al., 1994) . VEGF contributes to vascular permeability provokes dilatation and promote angiogenesis
Oxidative Stress and the Endometrial Cycle
Aerobic metabolism is associated with the generation of pro-oxidant molecules called free radicals, or reactive oxygen species (ROS) that include the hydroxyl radicals, superoxide anion, hydrogen peroxide, and nitric oxide.
There is a complex interaction of the pro-oxidants and antioxidants, resulting in the maintenance of the intracellular 
Role of VEGF in Menorrhagia
The observation that vascular repair is an obvious feature of menstruation does not mean that disturbance of this mechanism cause menorrhagia, but that there is other evidence which suggests that altered VEGF-A expression may be involved. To understand this, the multiple actions of VEGF-A need to be considered and placed within the context of the mechanisms of menstruation.
The two hypotheses currently used to explain heavy periods suggest either increased fibrinolytic activity, or enhanced vasodilatation. In the former circumstance, this is suggested by the finding of reduced platelet fibrin plug formation in menstrual endometrium compared with other parts of the body (Christiaens et al., 1980) , the presence of higher tPA concentrations in endometrium of women with objective menorrhagia (Sheppard, 1996) , and the observation that Tranexamic acid, which impairs fibrinolysis, reduces menstrual blood loss by about 50%. VEGF stimulates tPA synthesis by endothelial cells and increases vascular permeability, resulting in activation of the extravascular coagulation cascade with the consumption of fibrin (Pepper et al., 1991) . The release of VEGF by activated platelets provides a further means by which VEGF increases tPA release, as menstrual platelets are activated in the uterine cavity (Rees et al., 1984) .
These observations are particularly important, as they provide an explanation which bridges the vascular theories of menstruation with those of the coagulation system.
Pilot information suggests that, immune reactivity for VEGF-A is increased in women with menorrhagia.
The potent vasodilator, nitric oxide, is released by endometrium (Tseng et al., 1996) and VEGF stimulates NO release from endothelial cells (Papapetropoulos et al., 1997) . With the increased release of the vasodilatory PGI2, both of these actions would be expected to promote vasodilatation.
The recent finding that the proliferative activity of endothelial cells is doubled in endometrium of women with heavy periods (Kooy et al., 1996) further suggests that, disturbances of angiogenic growth factor expression or function could be involved in the pathology of menorrhagia. Increased levels of VEGF are found in the peritoneum of women suffering from endometriosis (Shifren et al., 1996) , which may provide a further link between menorrhagia and the establishment of ectopic endometrial explants. The close relationship between VEGF and the coagulation system and its possible effects on vascular tone further implicate disorders of VEGF expression with common pathologies of the female reproductive tract (Kooy et al., 1996) .
RESULTS
It shows that, serum VEGF-A level get reduced in all the three groups which were statistically significant, but the improvement was more in trial group C (p value >.001), in which patients took oral drug with uttar basti.
CONCLUSIONS
Darvyadi decoction and uttar basti with Darvyadi oil can be helpful in managing heavy bleeding related to DUB effectively, that is evidenced by reduced levels of biochemical marker VEGF-A. It can be use as a better alternative treatment for DUB.
